Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 4/2014

Open Access 01-10-2014 | Review

Clinical value of whole-body PET/CT in patients with active rheumatic diseases

Authors: Hiroyuki Yamashita, Kazuo Kubota, Akio Mimori

Published in: Arthritis Research & Therapy | Issue 4/2014

Login to get access

Abstract

Advanced imaging techniques may enable early diagnosis and monitoring of therapy in various rheumatic diseases. To prevent irreversible tissue damage, inflammatory rheumatic disease must be diagnosed and treated in pre-clinical stages, requiring highly sensitive detection techniques. Positron emission tomography (PET) provides highly sensitive, quantitative imaging at a molecular level, revealing the important pathophysiological processes underlying inflammation. This review provides an overview of the current utility of 18 F-fluorodeoxyglucose (FDG)-PET/computed tomography (CT) in patients with active rheumatic diseases such as rheumatoid arthritis, spondyloarthritis, polymyalgia rheumatica, adult-onset Still's disease, relapsing polychondritis, immunoglobulin G4-related disease, large-vessel vasculitis, Wegener's granulomatosis, polymyositis, and dermatomyositis. We also discuss the role of FDG-PET/CT in the diagnosis and monitoring of these diseases.
Appendix
Available only for authorised users
Literature
1.
Landewé RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, van Denderen JC, Westedt ML, Peeters AJ, Dijkmans BA, Jacobs P, Boonen A, van der Heijde DM, van der Linden S: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002, 46: 347-356. 10.1002/art.10083.CrossRef
2.
Ostergaard M, Hansen M, Stoltenberg M, Gideon P, Klarlund M, Jensen KE, Lorenzen I: Magnetic resonance imaging-determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis. Arthritis Rheum. 1999, 42: 918-929. 10.1002/1529-0131(199905)42:5<918::AID-ANR10>3.0.CO;2-2.CrossRef
3.
Kane D, Balint PV, Sturrock RD: Ultrasonography is superior to clinical examination in the detection and localization of knee joint effusion in rheumatoid arthritis. J Rheumatol. 2003, 30: 966-971.
4.
Koenigkam-Santos M, Sharma P, Kalb B, Oshinski JN, Weyand CM, Goronzy JJ, Martin DR: Magnetic resonance angiography in extracranial giant cell arteritis. J Clin Rheumatol. 2011, 17: 306-310. 10.1097/RHU.0b013e31822acec6.PubMedCentralCrossRef
5.
Denko N: Hypoxia, HIF1 and glucose metabolism in the solid tumor. Nature Rev Cancer. 2008, 8: 705-713. 10.1038/nrc2468.CrossRef
6.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T: Intratumoral distribution of flurine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992, 33: 1972-1980.
7.
Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N: High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995, 36: 1301-1306.
8.
Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS: HIF-1α is essential for myeloid cell-mediated inflammation. Cell. 2003, 112: 645-657. 10.1016/S0092-8674(03)00154-5.PubMedCentralCrossRef
9.
Matsui T, Nakata N, Nagai S, Nakatani A, Takahashi M, Momose T, Ohtomo K, Koyasu S: Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med. 2009, 50: 920-926. 10.2967/jnumed.108.060103.CrossRef
10.
Palmer WE, Rosenthal DI, Schoenberg OI, Fischman AJ, Simon LS, Rubin RH, Polisson RP: Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995, 196: 647-655. 10.1148/radiology.196.3.7644624.CrossRef
11.
Beckers C, Ribbens C, André B, Marcelis S, Kaye O, Mathy L, Kaiser MJ, Hustinx R, Foidart J, Malaise MG: Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med. 2004, 45: 956-964.
12.
Kubota K, Ito K, Morooka M, Mitsumoto T, Kurihara K, Yamashita H, Takahashi Y, Mimori A: Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med. 2009, 23: 783-791. 10.1007/s12149-009-0305-x.CrossRef
13.
Goerres GW, Forster A, Uebelhart D, Seifert B, Treyer V, Michel B, von Schulthess GK, Kaim AH: F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med. 2006, 31: 386-390. 10.1097/01.rlu.0000222678.95218.42.CrossRef
14.
Okamura K, Yonemoto Y, Arisaka Y, Takeuchi K, Kobayashi T, Oriuchi N, Tsushima Y, Takagishi K: The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT. Rheumatology (Oxford). 2012, 51: 1484-1491. 10.1093/rheumatology/kes064.CrossRef
15.
Elzinga EH, van der Laken CJ, Comans EF, Lammertsma AA, Dijkmans BA, Voskuyl AE: 2-Deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. Molecular Imaging Biology. 2007, 9: 357-360. 10.1007/s11307-007-0113-4.PubMedCentralCrossRef
16.
Ostendorf B, Mattes-György K, Reichelt DC, Blondin D, Wirrwar A, Lanzman R, Müller HW, Schneider M, Mödder U, Scherer A: Early detection of bony alterations in rheumatoid and erosive arthritis of finger joints with high-resolution single photon emission computed tomography, and differentiation between them. Skeletal Radiol. 2010, 39: 55-61. 10.1007/s00256-009-0761-3.CrossRef
17.
Okabe T, Shibata H, Shizukuishi K, Yoneyama T, Inoue T, Tateishi U: F-18 FDG uptake patterns and disease activity of collagen vascular diseases-associated arthritis. Clin Nucl Med. 2011, 36: 350-354. 10.1097/RLU.0b013e318212c858.CrossRef
18.
Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O’Connor PJ, Emery P: An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008, 58: 2958-2967. 10.1002/art.23945.CrossRef
19.
Elzinga EH, van der Laken CJ, Comans EF, Boellaard R, Hoekstra OS, Dijkmans BA, Lammertsma AA, Voskuyl AE: 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med. 2011, 52: 77-80. 10.2967/jnumed.110.076711.CrossRef
20.
Adams MC, Turkington TG, Wilson JM, Wong TZ: A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010, 195: 310-320. 10.2214/AJR.10.4923.CrossRef
21.
Szkudlarek M, Court P, Jacobsen S, Klarlund M, Thomsen HS, Ostergaard M: Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum. 2003, 48: 955-962. 10.1002/art.10877.CrossRef
22.
Kubota K, Ito K, Morooka M, Minamimoto R, Miyata Y, Yamashita H, Takahashi Y, Mimori A: FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT. Ann N Y Acad Sci. 2011, 1228: 29-38. 10.1111/j.1749-6632.2011.06031.x.CrossRef
23.
Miese F, Scherer A, Ostendorf B, Heinzel A, Lanzman RS, Kröpil P, Blondin D, Hautzel H, Wittsack HJ, Schneider M, Antoch G, Herzog H, Shah NJ: Hybrid 18F-FDG PET-MRI of the hand in rheumatoid arthritis: initial results. Clin Rheumatol. 2011, 30: 1247-1250. 10.1007/s10067-011-1777-3.CrossRef
24.
Yamashita H, Kubota K, Takahashi Y, Minamimoto R, Morooka M, Kaneko H, Kano T, Mimori A: Similarities and differences in fluorodeoxyglucose positron emission tomography/computed tomography findings in spondyloarthropathy, polymyalgia rheumatica and rheumatoid arthritis. Joint Bone Spine. 2013, 80: 171-177. 10.1016/j.jbspin.2012.04.006.CrossRef
25.
Nash P, Mease PJ, Braun J, van der Heijde D: Seronegative spondyloarthropathies: to lump or split?. Ann Rheum Dis. 2005, 64: 9-13.
26.
Godfrin B, Zabraniecki L, Lamboley V, Bertrand-Latour F, Sans N, Fournié B: Spondyloarthropathy with entheseal pain. A prospective study in 33 patients. Joint Bone Spine. 2004, 71: 557-562. 10.1016/j.jbspin.2003.10.010.CrossRef
27.
Taniguchi Y, Arii K, Kumon Y, Fukumoto M, Ohnishi T, Horino T, Kagawa T, Kobayashi S, Ogawa Y, Terada Y: Positron emission tomography/computed tomography: a clinical tool for evaluation of enthesitis in patients with spondyloarthritides. Rheumatology (Oxford). 2010, 49: 348-354. 10.1093/rheumatology/kep379.CrossRef
28.
Strobel K, Fischer DR, Tamborrini G, Kyburz D, Stumpe KD, Hesselmann RG, Johayem A, von Schulthess GK, Michel BA, Ciurea A: 18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis. Eur J Nucl Med Mol Imaging. 2010, 37: 1760-1765. 10.1007/s00259-010-1464-7.CrossRef
29.
Vijayant V, Sarma M, Aurangabadkar H, Bichile L, Basu S: Potential of (18)F-FDG-PET as a valuable adjunct to clinical and response assessment in rheumatoid arthritis and seronegative spondyloarthropathies. World J Radiol. 2012, 4: 462-468. 10.4329/wjr.v4.i12.462.PubMedCentralCrossRef
30.
Yamashita H, Kubota K, Takahashi Y, Minaminoto R, Morooka M, Ito K, Kano T, Kaneko H, Takashima H, Mimoiri A: Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. Mod Rheumatol. 2012, 22: 705-711. 10.3109/s10165-011-0581-x.CrossRef
31.
Chuang TY, Hunder GG, Ilstrup DM, Kurland LT: Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982, 97: 672-680. 10.7326/0003-4819-97-5-672.CrossRef
32.
Healey LA: Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum. 1984, 13: 322-328. 10.1016/0049-0172(84)90012-X.CrossRef
33.
Salvarani C, Cantini F, Olivieri I, Hunder GS: Polymyalgia rheumatica: a disorder of extraarticular synovial structures?. J Rheumatol. 1999, 26: 517-
34.
Salvarani C, Cantini F, Olivieri I, Barozzi L, Macchioni L, Niccoli L, Padula A, De Matteis M, Pavlica P: Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med. 1997, 127: 27-10.7326/0003-4819-127-1-199707010-00005.CrossRef
35.
Cantini F, Salvarani C, Olivieri I, Niccoli L, Padula A, Macchioni L, Boiardi L, Ciancio G, Mastrorosato M, Rubini F, Bozza A, Zanfranceschi G: Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol. 2001, 28: 1049-
36.
Moosig F, Czech N, Mehl C, Henze E, Zeuner RA, Kneba M, Schröder JO: Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis. 2004, 63: 870-873. 10.1136/ard.2003.011692.PubMedCentralCrossRef
37.
Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H: Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford). 2007, 46: 672-677. 10.1093/rheumatology/kel376.CrossRef
38.
Yamashita H, Kubota K, Takahashi Y, Minamimoto R, Morooka M, Kaneko H, Kano T, Mimori A: Clinical value of 18F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature. Mod Rheumatol. 2014, 24: 645-650. 10.3109/14397595.2013.850998.CrossRef
39.
Yamashita H, Takahashi H, Kubota K, Ueda Y, Ozaki T, Yorifuji H, Bannai E, Minamimoto R, Morooka M, Miyata Y, Okasaki M, Takahashi Y, Kaneko H, Kano T, Mimori A: Utility of fluorodeoxyglucose positron emission tomography/computed tomography for early diagnosis and evaluation of disease activity of relapsing polychondritis: a case series and literature review. Rheumatology (Oxford). 2014, 53: 1482-1490. 10.1093/rheumatology/keu147.CrossRef
40.
Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Sumida T, Mimori T, Tanaka Y, Tsubota K, Yoshino T, Kawa S, Suzuki R, Takegami T, Tomosugi N, Kurose N, Ishigaki Y, Azumi A, Kojima M, Nakamura S, Inoue D: A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012, 22: 1-14. 10.3109/s10165-011-0508-6.PubMedCentralCrossRef
41.
Shigekawa M, Yamao K, Sawaki A, Hara K, Takagi T, Bhatia V, Nishio M, Tamaki T, El-Amin H, Sayed Z-A, Mizuno N: Is 18F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis?. J Hepatobiliary Pancreat Sci. 2010, 17: 269-274. 10.1007/s00534-009-0172-9.CrossRef
42.
Ozaki Y, Oguchi K, Hamano H, Arakura N, Muraki T, Kiyosawa K, Momose M, Kadoya M, Miyata K, Aizawa T, Kawa S: Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol. 2008, 43: 144-151. 10.1007/s00535-007-2132-y.CrossRef
43.
Ebbo M, Grados A, Guedj E, Gobert D, Colavolpe C, Zaidan M, Masseau A, Bernard F, Berthelot JM, Morel N, Lifermann F, Palat S, Haroche J, Mariette X, Godeau B, Bernit E, Costedoat-Chalumeau N, Papo T, Hamidou M, Harlé JR, Schleinitz N: 18F-FDG PET/CT for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study. Arthritis Care Res (Hoboken). 2014, 66: 86-96. 10.1002/acr.22058.CrossRef
44.
Takahashi H, Yamashita H, Morooka M, Kubota K, Takahashi Y, Kaneko H, Kano T, Mimori A: The utility of FDG-PET/CT and other imaging techniques in the evaluation of IgG4-related disease. Joint Bone Spine. 2014, 81: 331-336. 10.1016/j.jbspin.2014.01.010.CrossRef
45.
Muto G, Yamashita H, Takahashi Y, Miyata Y, Morooka M, Minamimoto R, Kubota K, Kaneko H, Kano T, Mimori A: Large-vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT.Rheumatol Int. Mar 19 [Epub ahead of print].,
46.
Treglia G, Mattoli MV, Leccisotti L, Ferraccioli G, Giordano A: Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol. 2011, 30: 1265-1275. 10.1007/s10067-011-1828-9.CrossRef
47.
Ito K, Minamimoto R, Yamashita H, Yoshida S, Morooka M, Okasaki M, Mimori A, Kubota K: Evaluation of Wegener's granulomatosis using 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Ann Nucl Med. 2013, 27: 209-216. 10.1007/s12149-012-0675-3.PubMedCentralCrossRef
48.
Ozmen O, Tatci E, Gokcek A, Koksal D, Dadali Y, Ozaydin E, Arslan N: Integration of 2-deoxy-2-[18F] fluoro-D-glucose PET/CT into clinical management of patients with Wegener's granulomatosis. Ann Nucl Med. 2013, 27: 907-915. 10.1007/s12149-013-0769-6.CrossRef
49.
Owada T, Maezawa R, Kurasawa K, Okada H, Arai S, Fukuda T: Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis. J Rheumatol. 2012, 39: 1659-1665. 10.3899/jrheum.111597.CrossRef
50.
Tanaka S, Ikeda K, Uchiyama K, Iwamoto T, Sanayama Y, Okubo A, Nakagomi D, Takahashi K, Yokota M, Suto A, Suzuki K, Nakajima H: [18F]FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2013, 52: 1271-1278. 10.1093/rheumatology/ket112.CrossRef
51.
Beckers C, Jeukens X, Ribbens C, André B, Marcelis S, Leclercq P, Kaiser MJ, Foidart J, Hustinx R, Malaise MG: (18)F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging. 2006, 33: 275-280. 10.1007/s00259-005-1952-3.CrossRef
52.
Sato M, Inubushi M, Shiga T, Hirata K, Okamoto S, Kamibayashi T, Tanimura K, Tamaki N: Therapeutic effects of acupuncture in patients with rheumatoid arthritis: a prospective study using (18)F-FDG-PET. Ann Nucl Med. 2009, 23: 311-316. 10.1007/s12149-009-0238-4.CrossRef
53.
Polisson RP, Schoenberg OI, Fischman A, Rubin R, Simon LS, Rosenthal D, Palmer WE: Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 819-825. 10.1002/art.1780380616.CrossRef
54.
van Dongen GA, Visser GW, Lub-de Hooge MN, De Vries EG, Perk LR: Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007, 12: 1379-1389. 10.1634/theoncologist.12-12-1379.CrossRef
Metadata
Title
Clinical value of whole-body PET/CT in patients with active rheumatic diseases
Authors
Hiroyuki Yamashita
Kazuo Kubota
Akio Mimori
Publication date
01-10-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-014-0423-2

Other articles of this Issue 4/2014

Arthritis Research & Therapy 4/2014 Go to the issue

Research article

Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint

Research article

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

Research article

Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis

Research article

Extracorporeal shockwave therapy in osteoporotic osteoarthritis of the knee in rats: an experiment in animals

Research

Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction

Research article

18 F-Fluoride positron emission tomography/computed tomography for noninvasive in vivo quantification of pathophysiological bone metabolism in experimental murine arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits